✦ LIBER ✦

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

✍ Scribed by Wedemeyer, Heiner; Jensen, Donald M.; Godofsky, Eliot; Mani, Nina; Pawlotsky, Jean-Michel; Miller, Veronica

Book ID: 118759137
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 569 KB
Volume: 56
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.25888

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Virologic Monitoring of Hepatitis B Viru

Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach

✍ Jean–Michel Pawlotsky; Geoffrey Dusheiko; Angelos Hatzakis; Daryl Lau; George La 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Viral response guided therapy for hepati

Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents

✍ Mark D. Berzsenyi; Stuart K. Roberts 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB

Inhibition of bovine viral diarrhea viru

Inhibition of bovine viral diarrhea virus in vitro by xanthohumol: Comparisons with ribavirin and interferon-α and implications for the development of anti-hepatitis C virus agents

✍ Ni Zhang; Zhengwen Liu; Qunying Han; Jinghong Chen; Sai Lou; Jianming Qiu; Guoyu 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 863 KB

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response

✍ Brian L. Pearlman; Carole Ehleben 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may